University of Nebraska Medical Center

DigitalCommons@UNMC
Journal Articles: Epidemiology

Epidemiology

2021

Utility of Repeat Testing for COVID-19: Laboratory Stewardship
When the Stakes are High
Lindsey M. Rearigh
Angela L. Hewlett
Paul D. Fey
M. Jana Broadhurst
David Brett-Major

See next page for additional authors

Follow this and additional works at: https://digitalcommons.unmc.edu/coph_epidem_articles
Part of the Epidemiology Commons

Authors
Lindsey M. Rearigh, Angela L. Hewlett, Paul D. Fey, M. Jana Broadhurst, David Brett-Major, Mark Rupp, and
Trevor Van Schooneveld

Infection Control & Hospital Epidemiology (2021), 42, 338–340
doi:10.1017/ice.2020.397

Concise Communication

Utility of repeat testing for COVID-19: Laboratory stewardship when
the stakes are high
Lindsey M. Rearigh DO1

, Angela L. Hewlett MD, MS1, Paul D. Fey PhD2, M. Jana Broadhurst MD, PhD2,

David M. Brett-Major MD, MPH3, Mark E. Rupp MD1 and Trevor C. Van Schooneveld MD1
1

Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, Nebraska, 2Division of Pathology and Microbiology, University of Nebraska
Medical Center, Omaha, Nebraska and 3Department of Epidemiology, University of Nebraska Medical Center, Omaha, Nebraska

Abstract
As the coronavirus disease 2019 (COVID-19) continues to circulate, testing strategies are of the utmost importance. Given national shortages
of testing supplies, personal protective equipment, and other hospital resources, diagnostic stewardship is necessary to aid in resource
management. We report the low utility of serial testing in a low-prevalence setting.
(Received 4 May 2020; accepted 29 July 2020; electronically published 3 August 2020)

Rapid and accurate testing for severe acute respiratory coronavirus
virus 2 (SARS-CoV-2) during the coronavirus disease 2019
(COVID-19) pandemic is essential to limit transmission and
to aid in appropriate management of hospitalized patients.
Understanding of the performance of COVID-19 nucleic acid
testing in clinical settings is evolving. Many false-negative
reverse transcription polymerase chain reaction (rt-PCR) tests
have been reported, raising concerns regarding infection control
and patient placement.1–3 Apprehension regarding transmission
prevention along with lack of data on test performance have led
to the ordering of serial tests for persons under investigation.
We assessed the value of repeat testing for COVID-19 after an initial negative result to evaluate test performance and to determine
whether repeat testing is necessary.
Methods
We retrospectively reviewed inpatient and outpatient test results
among patients who presented to our academic medical center
in Omaha, Nebraska, from March 10 through April 28, 2020.
Patients with a negative or inconclusive COVID-19 rt-PCR test followed by at least 1 additional test were included. Patients who had
testing separated by >14 days were excluded because there was
significant risk of new exposure during that period, prompting
testing. Basic demographic information and clinician indication
for testing were collected via electronic medical record review.
Testing was performed with the cobas SARS CoV-2 on the
Roche 6800 platform, and a second laboratory developed an
RT-PCR test (NECoV19). The cobas SARS CoV-2 uses primers
and probes that detect the ORF1a and E genes whereas the
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NECoV19 assay detects the E and N genes. Using the NECoV19
assay, if the E-gene was detected, the same RNA sample was
retested with the E-gene and N-gene as targets. If either the E-gene
or the N-gene or both were detected, the test was positive.
However, if gene targets were inconsistently identified and neither
the E-gene nor the N-gene was not detected by the repeat test, the
test was inconclusive.
Results
In total, 275 patients with initially negative or inconclusive test
results (94% negative, 6% inconclusive) underwent at least 1 additional test. Results of the second test were 98.5% (271 of 275) negative, 0.5% positive (1 of 275), and 1% inconclusive (3 of 275).
Furthermore, 40 patients (14.5%) underwent a third test, with
97% negative results (39 of 40) and 3% positive results (1 of 39).
Also, 10 patients (1.5%) underwent >3 tests, with no positive
results. Patient characteristics, indications for testing, and sample
sources are outlined in Table 1. Median time from symptom onset
to initial test was 3 days, with 69% of initial tests performed in the
first week of illness and 17% performed on asymptomatic patients
(primarily preprocedural screening). All samples were obtained
from the respiratory tract. The most testing was performed via
nasopharyngeal (NP) swab, although lower respiratory tract (LRT)
sampling was more common with repeat testing. Median time
between testing was longer among second and third tests compared to first and second tests (3.8 days vs 1 day). The most
common indication for repeat testing was signs and symptoms
concerning for COVID-19 infection or evidence of LRT infection
on imaging via either chest CT or x-ray: 58% for the second testing
indication and 50% for the third testing indication.
Discussion
We found that repeat testing in patients who had initially tested
negative had very low utility. Of 275 patients tested, 2 tested
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Table 1. Population Characteristics and Testing Indication
No. (%)
(N = 275)

Characteristic
Median age, y (range)

62 (1–94)

Male sex

143 (58)
st

Median time between 1 and 2

nd

tests, d (range)

1.0 (0–14)

Median time between 2nd and 3rd tests, d (range)

3.8 (1–14)

Time to initial testing from symptom onset
1–7 d

190 (69)

8–14 d

27 (10)

>14 d

10 (4)
a

Screening d

48 (17)

2nd test indicationb
Symptoms suggestive of COVID-19 infection or evidence
of LRTI on imaging

158 (58)

Immunosuppressed patientc

55 (20)

High-risk exposure

d

27 (10)

Additional screening neededa
Other

e

69 (25)
21 (8)

3rd test indicationb (N = 40)
Symptoms suggestive of COVID-19 or evidence of LRTI
on imaging
Immunosuppressed patientc

3 (7)

High-risk exposured
Additional screening needed

20 (50)

2 (5)
a

19 (48)

Sample source
1st test (N = 275)
Nasopharyngeal
Tracheal aspirate/sputum

272 (99)
3 (1)

2nd test (N = 275)
Nasopharyngeal
Tracheal aspirate/sputum

255 (93)
20 (7)

rd

3 test (N = 40)
Nasopharyngeal

31 (77)

Tracheal aspirate/sputum

9 (23)

a

Screening was required for planned procedures, for patients residing in a group setting, and
for those with frequent contact with healthcare facilities. Additional screening was required
prior to hospital discharge.
b
Patients could have >1 indication for 2nd and 3rd testing.
c
Included patients on immunosuppressive medications, transplant recipients, patients with
active cancer on chemotherapy, and patients with HIV with CD4 count <200.
d
Includes exposure to a person who is a known positive or currently under investigation for
COVID-19.
e
Reason not documented or clinician requesting additional testing.

thought to be due to waning viral load levels in the upper respiratory region.6–8
Diagnostic stewardship is essential to improving the efficiency
of the testing process and to conserve testing supplies and personal
protective equipment (PPE) given critical national shortages.9
Patient flow and bed availability are also affected by duplicate testing, which can delay patient transfer out of isolation rooms as well
as increase PPE utilization while test results are pending. Further
patient work-up and definitive diagnoses can also be delayed due to
physician anchoring and confirmation biases. Equipment such as
swabs and reagents to perform testing are limited, emphasizing the
need to safely limit testing particularly in low-prevalence areas to
allocate resources were more testing is necessary.
Based on our findings, we modified our testing recommendations to state that a single appropriately obtained NP swab performed within the first 7 days of illness is generally adequate to
rule out COVID-19. If clinical suspicion persists due to high-risk
exposure or classic clinical presentation, additional testing should
be obtained. Patients presenting with pneumonia may benefit from
repeat testing utilizing specimens from the LRT. Preference for collection of LRT specimens in patients with pneumonia is in line with
both the World Health Organization and Centers for Disease
Control recommendations.10,11 Our guideline revision was implemented via education of our COVID teams and ID physicians. Our
current practice of determining the need for additional testing
involves patient review by a multidisciplinary team, including an
infectious diseases physician with experience in managing patients
with COVID-19. The ID physician leading this team generally
determines whether additional testing is needed after input from
the primary team.
Limitations of this study include a relatively low COVID-19
community prevalence (average 7% of tests positive), which limits
its generalizability to high-prevalence settings. Testing in our
facility utilized 2 assays that demonstrated similar performance
for COVID-19 detection, but these results may not be applicable
to other assays. Repeat testing was not systematically employed
and cases may have potentially been missed, but at this time we
are unaware of any missed COVID-19 cases in our facility.
In conclusion, we found little benefit of repeat testing in
patients who presented early in their illness. We have adopted diagnostic testing stewardship, limiting testing to a single nasopharyngeal swab sample in most cases. Facilities should continually
evaluate test performance and utilization to maximize the value
of such tests, especially when faced with limited resources.
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